CN1111412C - Notoginseng total saponin soft capsule and its preparation process - Google Patents
Notoginseng total saponin soft capsule and its preparation process Download PDFInfo
- Publication number
- CN1111412C CN1111412C CN98106597A CN98106597A CN1111412C CN 1111412 C CN1111412 C CN 1111412C CN 98106597 A CN98106597 A CN 98106597A CN 98106597 A CN98106597 A CN 98106597A CN 1111412 C CN1111412 C CN 1111412C
- Authority
- CN
- China
- Prior art keywords
- notoginseng total
- capsule
- total saponin
- glycerol
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000180649 Panax notoginseng Species 0.000 title claims abstract description 61
- 235000003143 Panax notoginseng Nutrition 0.000 title claims abstract description 61
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 47
- 229930182490 saponin Natural products 0.000 title claims abstract description 47
- 150000007949 saponins Chemical class 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000007901 soft capsule Substances 0.000 title abstract description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 85
- 239000002775 capsule Substances 0.000 claims abstract description 47
- 239000007788 liquid Substances 0.000 claims abstract description 24
- 108010010803 Gelatin Proteins 0.000 claims abstract description 15
- 239000008273 gelatin Substances 0.000 claims abstract description 15
- 229920000159 gelatin Polymers 0.000 claims abstract description 15
- 235000019322 gelatine Nutrition 0.000 claims abstract description 15
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 15
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 239000003381 stabilizer Substances 0.000 claims abstract description 8
- 235000011187 glycerol Nutrition 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 238000005516 engineering process Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 230000002421 anti-septic effect Effects 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000009413 insulation Methods 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 239000000084 colloidal system Substances 0.000 claims description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 3
- 235000021050 feed intake Nutrition 0.000 claims description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 3
- 229960002216 methylparaben Drugs 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 3
- 235000013772 propylene glycol Nutrition 0.000 claims description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 3
- MOZDKDIOPSPTBH-UHFFFAOYSA-N Benzyl parahydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OCC1=CC=CC=C1 MOZDKDIOPSPTBH-UHFFFAOYSA-N 0.000 claims description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- 230000036961 partial effect Effects 0.000 claims description 2
- GJLNWLVPAHNBQN-UHFFFAOYSA-N phenyl 4-hydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OC1=CC=CC=C1 GJLNWLVPAHNBQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims description 2
- 239000013557 residual solvent Substances 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 235000017709 saponins Nutrition 0.000 abstract description 41
- 239000003814 drug Substances 0.000 abstract description 19
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 206010008118 cerebral infarction Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 201000006474 Brain Ischemia Diseases 0.000 description 11
- 206010008120 Cerebral ischaemia Diseases 0.000 description 11
- 239000009692 xuesetong Substances 0.000 description 11
- 230000002490 cerebral effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 7
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000007903 gelatin capsule Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 230000000302 ischemic effect Effects 0.000 description 7
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 7
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 5
- 108010003541 Platelet Activating Factor Proteins 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 206010053567 Coagulopathies Diseases 0.000 description 4
- 244000131316 Panax pseudoginseng Species 0.000 description 4
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000035602 clotting Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 231100001252 long-term toxicity Toxicity 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002183 duodenal effect Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000001951 hemoperfusion Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 210000004129 prosencephalon Anatomy 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 210000001202 rhombencephalon Anatomy 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940083466 soybean lecithin Drugs 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010021703 Indifference Diseases 0.000 description 2
- 208000001705 Mouth breathing Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000031354 Hyphema Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- -1 electuary Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a notoginseng total saponin soft capsule and its preparation process. The product consists of two parts, namely liquid medicine and a capsule shell, and is characterized in that each part of the liquid medicine contains 40-250 mg of panax notoginseng saponins, 400 mg of a solvent and 500 mg of a stabilizer by weight, and the capsule shell contains 10 parts of gelatin, 3.25-3.35 parts of glycerol (by weight ratio) and a preservative. The soft capsule has the advantages that the soft capsule taking the panax notoginseng saponins as the main active ingredient and the preparation process thereof are provided, the product is an oral administration preparation form, the defects of the existing preparation form can be overcome, the bioavailability is high, and the standards of the preparation forms in aspects of appearance, hardness, disintegration degree and the like and physical and chemical stability are met.
Description
Technical field
The present invention relates to contain the soft capsule oral drugs and the preparation technology thereof of Radix Notoginseng total arasaponins effective dose.
Background technology
Radix Notoginseng total arasaponins (Panax Notoginseng Saponins) is total Saponin that the reed head of araliaceae ginseng plant Radix Notoginseng (Panax Notoginseng (Burk.) F.H.Chen) extracts by certain technology, be faint yellow indefiniteness powder, bitter but slightly sweet taste, soluble in water, methanol, ethanol, be insoluble in acetone, ether and benzene, easily the moisture absorption.Have blood circulation promoting and blood stasis dispelling, promote blood circulation active, the effect of anticoagulant and cerebral blood flow increasing amount.Be used for apoplexy sequela, central retinal vein occlusion, hyphema etc.Radix Notoginseng total arasaponins toxicity is low, and side effect is minimum.
" XUESAITONG ZHUSHEYE " that with Radix Notoginseng total arasaponins be main effective ingredient has better curative effect to the paralysis of cerebral infarction and apoplexy sequela performance, and be harmless to the heart, liver,kidney,spleen stomach function regulating function, also do not have obvious toxic-side effects.With Radix Notoginseng total arasaponins is that the oral formulations of main effective ingredient has hard capsule, electuary, tablet.Existing oral formulations such as tablet and hard capsule, wherein effective ingredient Radix Notoginseng total arasaponins dissolution velocity in aqueous medium is slower, the conglomeration of easily being clamminess in the course of dissolution, luming, dissolving is relatively more difficult again; And main effective ingredient such as Rb1 and Rg1 equimolecular quantity are bigger in the Radix Notoginseng total arasaponins, and digestive tract absorbs slow and few, and principal agent excretes through feces in a large number, and bioavailability is low.Therefore existing oral formulations can't reach ideal effect to apoplexy, angina pectoris etc., only can be with building body, blood fat reducing, improve health care such as cardiovascular disease and be applied to clinical.The clinical use of injection is convenient not as oral formulations, and safety is not as oral formulations.The Chinese medicine that pollutes of commute particularly is though also be difficult to guarantee the stable of its effective ingredient through sterilization.Quality problems such as variable color, crystallization or precipitation just often appear in " XUESAITONG ZHUSHEYE " product of existing many producers.Have research data to show in addition, cardiovascular patient is comparatively responsive to metal ions such as sodium ion, and particularly a large amount of sodium ion can limit the Clinical Application scope.Sodium ion is just arranged in the XUESAITONG ZHUSHEYE.Moreover the frangible rapid wear of aqueous injection ampoule, can freeze winter in the north.
Summary of the invention
The purpose of this invention is to provide a kind of is the notoginseng total saponin capsule and the preparation technology thereof of main effective ingredient with Radix Notoginseng total arasaponins, product is an oral administered dosage form, can overcome the shortcoming of existing dosage form, the bioavailability height satisfies the standard of such dosage form aspect outward appearance, hardness, disintegration etc. and physical and chemical stability.
Product of the present invention is made of medicinal liquid and softgel shell two large divisions, it is characterized in that medicinal liquid by weight every contain Radix Notoginseng total arasaponins 40-250 milligram, and contain solvent 250-400 milligram, stabilizing agent 200-500 milligram, the gelatin that contains 10 parts of weight in the softgel shell, 3.25-3.35 the glycerol of part weight, and antiseptic.
Solvent is one or more in liquid polyethylene glycol, isopropyl alcohol, tween 80, glycerol, propylene glycol, water and the vegetable oil.
Antiseptic is one or more in glycerol, propylene glycol, methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, benzyl p-hydroxybenzoate, the P-hydroxybenzoic acid phenyl ester
But one or more in stabilizing agent water, glycerol, tween 80, ethyoxyl castor oil hydrogenated (GremophorRH 40), soybean lecithin, Cera Flava, aluminum monostearate, ethyl cellulose, the solid polyethylene glycol.
Gelatin, glycerol proportioning are difficult to grasp in the prescription of softgel shell.The amount of glycerol is too many, and softgel shell is softer, than being easier to extrusion; The amount of glycerol very little, softgel shell is harder, crisp, influences the quality stability and the disintegration time of soft capsule.We have carried out detailed experimental study to the gelatin of softgel shell, the proportioning of glycerol, have obtained a proportioning preferably at last.
An amount of gelatin is added in the rustless steel glue pot, add suitable quantity of water again, airtight, 70 ℃ are incubated 3 hours, add glycerol, the antiseptic of test consumption more respectively, stir, vacuumize degassing 2 hours, put into 70 ℃ of insulations of gelatin heat-preserving container standing over night, second day, the moulding ball, drying at room temperature, keep sample and investigate three months, examination softgel shell outward appearance and physical property, the result is as follows:
The index content of the test | Gelatin 30kg glycerol 3.0kg | Gelatin 10kg glycerol 3.2kg | Gelatin 10kg glycerol 3.25-3.35kg | Gelatin 10kg glycerol 3.4kg | Gelatin 10kg glycerol 3.6kg |
Softgel shell outward appearance and physical property | Too firmly, easily crisp | Too firmly, easily crisp | Suitable | Softer, the easy moisture absorption | Softer, the easy moisture absorption |
Illustrate: the softgel shell prescription that is filtered out is applicable to the place of warm moist.
By above test, can reach a conclusion, should contain 10 parts in gelatin in the prescription of softgel shell, glycerol 3.25-3.35 part (weight ratio)
Every of soft gelatin capsule contains principal agent---and the amount of Radix Notoginseng total arasaponins is determined; Consider the size of economic factor and selected every ball easy to prepare, finally can determine the liquid formula of embodiment.
Contain in the optimum formula of product of the present invention: component amount (gram/grain) Radix Notoginseng total arasaponins 0.04-0.25 solvent 0.25-0.40 stabilizing agent 0.02-0.05
The preparation technology of notoginseng total saponin capsule may further comprise the steps:
Technology 1: after Radix Notoginseng total arasaponins beaten powder and cross the 80-120 mesh sieve, by joining in the liquid polyethylene glycol, heating made the solution insulation at 50-70 ℃ and stir and make its dissolving under stirring, add entry and glycerol etc. after the dissolving, stirring makes its mix homogeneously, filter, outgas back pelleting, drying, promptly.
Technology 2: after Radix Notoginseng total arasaponins beaten powder and cross the 80-120 mesh sieve, feed intake by the prescription proportioning, earlier with the stabilizing agent thermosol in partial solvent, the thermosol thing is added in the residual solvent that is preheating to 35-45 ℃ lentamente, the limit edged stirs again, and then various solids are added one by one, fully mix each back that adds, moistening fully to guarantee, cross colloid mill and pulverize back pelleting, drying, promptly.
This product is the yellow transparent soft capsule.
It is the notoginseng total saponin capsule and the preparation technology thereof of main effective ingredient with Radix Notoginseng total arasaponins that good effect of the present invention has provided a kind of, product is an oral administered dosage form, can overcome the shortcoming of existing dosage form, the bioavailability height satisfies the standard of such dosage form aspect outward appearance, hardness, disintegration etc. and physical and chemical stability.
The specific embodiment
The present invention is by above-mentioned prepared, and its detailed component is provided by the following example, but protection scope of the present invention is not limited to this.
An amount of capsule shells 0.17 of embodiment 1 component amount (gram/grain) Radix Notoginseng total arasaponins 0.1 Polyethylene Glycol, 0.33 glycerol, 0.023 water
An amount of capsule shells 0.19 of embodiment 2 component amount (gram/grain) Radix Notoginseng total arasaponins 0.15 isopropyl alcohol, 0.35 ethyoxyl castor oil hydrogenated, 0.04 glycerol, 0.03 water
Embodiment 3 component amounts (gram/grain) an amount of capsule shells 0.14 embodiment of total saponin 0.05 polyethylene glycol of pseudo-ginseng 0.27 ethyoxyl rilanit special, 0.041 glycerine, 0.04 water 4 component amounts (gram/grain) an amount of capsule shells 0.19 of pseudo-ginseng total saponin 0.2 liquid polyethylene glycol 0.4 solid polyethylene glycol, 0.018 glycerine, 0.03 water
Embodiment 5 component amounts (gram/grain) an amount of capsule shells 0.15 of pseudo-ginseng total saponin 0.1 corn oil 0.30 soybean lecithin, 0.01 beeswax, 0.03 water
Embodiment 6 component amounts (gram/grain) an amount of Tween-80 0.003 soya-bean oil 0.17 soybean lecithin, 0.006 ethyl cellulose (100cps) of total saponin 0.05 water of pseudo-ginseng 0.025 capsule shells 0.12
The composition of capsule (shell) the epithelium liquid of embodiment 1 to 4:
Gelatin 100kg
Glycerol 35kg
Water is an amount of
Methyl parahydroxybenzoate 0.22kg
Propyl p-hydroxybenzoate 0.055kg
The composition of capsule (shell) the epithelium liquid of embodiment 5 to 6:
Gelatin 100kg
Glycerol 33kg
Water is an amount of
Ethylparaben 0.25kg
The preparation technology of embodiment is:
Technology 1: after Radix Notoginseng total arasaponins beaten powder and cross 100 mesh sieves, join gradually under stirring in the liquid polyethylene glycol, heating makes the solution insulation about 60 ℃ and stir and make its dissolving, add entry and glycerol etc. after the dissolving, stirring makes its mix homogeneously, filter, outgas back pelleting, drying, promptly.Perhaps:
Technology 2: after Radix Notoginseng total arasaponins beaten powder and cross 100 mesh sieves, feed intake by the prescription proportioning.Earlier with the stabilizing agent thermosol in an amount of fluid matrix, the thermosol thing is added lentamente in the residue substrate that is preheating to 40 ℃ again, the limit edged stirs, and then various solids such as principal agent are added one by one, fully mix each back that adds, moistening fully to guarantee, cross colloid mill and pulverize back pelleting, drying, promptly.
According to the requirement under new drug (Chinese medicine) the stability test capsule item, to notoginseng total saponin capsule three batch samples room temperature condition, and illumination (is according to 240 hours under the 2800LX in illuminance) and humidity effect factor carried out the quality observation, and measured every data, the result is as follows:
Table 1 970125-1 criticizes the room temperature preliminary result of investigation that keeps sample
Keep sample the time (moon) | Outward appearance | Thin layer chromatography | Disintegration (minute) | Rb1 content (%) | Rg content (%) | Total saponin content (%) |
0 | Complete soft gelatin capsule includes yellow clear and bright thick liquid | Principal spot is consistent with reference substance | 6.5 | 37.52 | 28.48 | 100.05 |
1 | The same | The same | 8 | 37.40 | 28.21 | 99.68 |
3 | The same | The same | 9.5 | 37.22 | 28.07 | 99.07 |
6 | The same | The same | 15 | 37.01 | 27.74 | 98.89 |
12 | The same | The same | 17 | 36.84 | 27.51 | 98.02 |
Table 2 970125-2 criticizes the room temperature preliminary result of investigation that keeps sample
Keep sample the time (moon) | Outward appearance | Thin layer chromatography | Disintegration (minute) | Rb1 content (%) | Rg1 content (%) | Total saponin content (%) |
0 | Complete soft gelatin capsule includes yellow clear and bright thick liquid | Principal spot is consistent with reference substance | 6.5 | 36.02 | 29.73 | 97.82 |
1 | The same | The same | 7 | 35.86 | 29.63 | 97.53 |
3 | The same | The same | 8.5 | 35.75 | 29.11 | 97.22 |
6 | The same | The same | 14 | 35.90 | 28.90 | 97.59 |
12 | The same | The same | 17 | 35.01 | 27.81 | 96.24 |
Table 3 970125-3 criticizes the room temperature preliminary result of investigation that keeps sample
Keep sample the time (moon) | Outward appearance | Thin layer chromatography | Disintegration (minute) | Rb1 content (%) | Rg1 content (%) | Total saponin content (%) |
0 | Complete soft gelatin capsule includes yellow clear and bright thick liquid | Principal spot is consistent with reference substance | 7 | 35.09 | 29.03 | 98.61 |
1 | The same | The same | 7 | 34.87 | 28.54 | 98.24 |
3 | The same | The same | 9 | 34.94 | 28.48 | 98.42 |
6 | The same | The same | 14 | 34.38 | 28.61 | 97.98 |
12 | The same | The same | 18 | 34.06 | 28.32 | 96.79 |
Table 4 light is to the influence of notoginseng total saponin capsule
Lot number | Outward appearance | Thin layer chromatography | Disintegration (minute) | Rb1 content (%) | Rg1 content (%) | Total saponin content (%) |
970125 -1 | Complete soft gelatin capsule includes yellow clear and bright liquid | No change | 15 | 36.91 | 28.03 | 99.22 |
970125 -2 | The same | The same | 13 | 35.77 | 29.32 | 97.36 |
970125 -3 | The same | The same | 14 | 34.80 | 28.19 | 98.23 |
Table 5 humidity is to the influence of notoginseng total saponin capsule
Project condition lot number | Outward appearance | Thin layer chromatography | Disintegration (minute) | Rb1 content (%) | Rg1 content (%) | Total saponin content (%) |
25 ℃ of RH75% 970125-2 of 970125-1 (sealing) 970125-3 | Complete soft gelatin capsule, it is the same to include yellow clear and bright thick liquid | No change no change no change | 10 10 9 | 37.28 35.82 34.91 | 28.31 29.28 28.66 | 99.81 97.43 98.19 |
25 ℃ of RH90% 970125-2 of 970125-1 (sealing) 970125-3 | Complete soft gelatin capsule, it is the same to include yellow clear and bright thick liquid | No change no change no change | 12 12 10 | 37.03 35.23 34.41 | 28.14 28.72 27.84 | 99.89 97.24 97.52 |
Annotate: be defined as the disintegration of soft capsule: 1 hour with interior (64 pages of two appendix of in 1995 version of Chinese Pharmacopoeia).Content is limited to 90-110%.
The present invention is by its performance of following evidence: one, animal acute toxicity test
Material:
1, notoginseng total saponin capsule: every ball contains Radix Notoginseng total arasaponins 100mg.Research and development centre of Kunming Medicine Stock Co., Ltd provides, lot number: the 970125-2. heating, and the adding distil water dissolved dilution is to required dosage concentration, and 38 ℃ of water-soluble constant temperature are standby:
2, laboratory animal: the ICR mice is provided by Yunnan Province natural drug pharmacology key lab, (Yun Weidong manages A12 number) male and female half and half, and W:19-21g, it is identical with the common mice in this chamber to observe feeding environment.
Test method and dosage regimen:
Sun Shi improvement Kou Shi composite accounting design dosage regimen is pressed in prerun before the formal test, is divided into five groups, press 0.4ml/10g and irritate stomach, successive administration is 2 times in the 6h, medicinal liquid 0.8 proportional diluted, 2 dosages of maximal dose group are 10g/kg, animal random packet, 10 every group, medicine front 2h stops eating, normal breeding observing behind the medicine, and record poisoning manifestations and death condition, dead animal cuts open inspection, the toxic pathological changes of each main organs of perusal, surviving animals continues one week of breeding observing.
Result of the test:
In the 6h part animal dead is arranged promptly after the high dose group administration for the first time, animal dead mostly occurs in 24h behind the medicine, and part animal loose stool is not taken food calmness.Dead animal the intestines and stomach topping up, inflation, mesentery hyperemia.48h not dead animal can healthy survival, recovers normal in the week day by day, administration situation and the results are shown in following table:
Notoginseng total saponin capsule acute toxicity test in mice (ig)
LD50=6730mg/kgLD50 95% credible 6730 ± 1260mg/kg two, the long-term toxicity test for animals of being limited to
Group dosage (mg/kg) number of animals (only) death toll (only) survival number (only) 1 10,000 10 912 8,000 10 733 6,400 10 554 5,200 10 285 4,100 10 0 10 |
Material and method:
1, medicine: notoginseng total saponin capsule is provided by Kunming Medicine Stock Co., Ltd, lot number: 970125-1, and specification is the 100mg/ ball, every 045ml contains principal agent 100mg.
2, animal: 80 of SD rats, male and female half and half provide (Yun Weidong manages A12 number) by Yunnan Province natural drug pharmacology key lab.
3, method: animal is divided into 4 groups at random, 20 every group, male and female half and half, sub-cage rearing is observed a week before the dispensing, treats that situations such as each treated animal activity, feed, feces are all no abnormal, begins dispensing then.
(1) small dose group: press 150mg/kg/ day administration.
(2) dosage group in: press 450mg/kg/ day administration.
(3) heavy dose of group: press 750mg/kg/ day administration.
(4) matched group: give blank solvent.
Above-mentioned four groups all by 0.3375ml/100g, every morning is irritated stomach once, amounts to 56 days, not drug withdrawal of centre.
Inspection item: weigh weekly, and adjust dosage thereupon, cage is looked on and is examined just character etc. of fur, eye, nose, mucosa, breathing, behavior, activity, feed, drinking-water and two; After medication finished, five hematological indices were checked in blood sampling: erythrocyte (RBc), leukocyte (WBc), platelet (PLT), hematochrome (Hb) and leukocyte differential count;
11 blood parameters: alanine aminotransferase (ALT), serum glutamic oxalacetic transaminase (AST), total serum protein (TP), serum urea nitrogen (BUN), creatinine (Crea), T-CHOL (T-CHO), blood glucose (Glu), albumin (ALB).
AST/ALT, A/G; 2/3 animal does the pathology inspection; System's postmortem; The heart, liver, spleen, lung, kidney device coefficient; Brain, the heart, liver, spleen, lung, kidney, adrenal gland, thymus, ovary, testis, uterine cancer cell are learned the animal of light microscopy checking and 1/3 and are retained 2 weeks of observation.
Result of the test:
1, each dosage group of notoginseng total saponin capsule and blank solvent matched group are all movable normal in 56 day experimental period, and behavior is active, and the hair color smoothness does not see that feces is unusual, none death.
2, four treated animal body weight gain situation basically identicals.
3, hematological examination, each dosage group of notoginseng total saponin capsule and matched group be the indifference opposite sex relatively all.
4, blood biochemical detects, and male Mus ALT is higher than the matched group except that low dose, and all the other and matched group be the indifference opposite sex relatively all.
5, the brain of four treated animals, the heart, spleen, lung, kidney, the adrenal gland, thymus, ovary, testis, 11 kinds of internal organs outward appearances such as uterus are normal, and pathological anatomy and histopathologic examination all do not have special pathological change.
Notoginseng total saponin capsule adult's consumption 15mg/kg/ day, in view of the above, the rat long term toxicity test, large, medium and small dosage is equivalent to 50,30 of the consumption of being grown up respectively.And 10 times, so adopt the 1/50 heavy dose of upper limit as clinical application, promptly 15mg/kg/ day is safe.
In view of this product mice LD50 (6730mg/kg) is more than 400 times of clinical recommended dose, the every index of long term toxicity test was no abnormal in 56 days, exempted to do the pathology inspection so retain animal, and can exempt to do the long term toxicity test of dog.
Three, the main pharmacodynamics of notoginseng total saponin capsule experiment:
Experiment material:
(1) medicine: notoginseng total saponin capsule (Kunming Medicine Stock Co., Ltd, lot number: 970125, get capsule psychological treatment liquid during experiment and dilute), XUESAITONG ZHUSHEYE (Kunming Medicine Stock Co., Ltd, lot number: 970351-07) with normal saline
(2) animal: mice, the Kunming kind, rat, the SD kind, all available from Yunnan Province natural drug pharmacology key lab rabbit, male and female half and half, 2.0-3.0kg is available from animal section of unming Medical College.
(3) other: 722 type visible spectrophotometers, BS-631 type platelet aggregation instrument, MP120-1 type electronic balance, reagent are analytical pure or medicinal specification (wherein, platelet activating factor and arachidonic acid are Sigma company product, and adenosine diphosphate (ADP) is Switzerland's import packing).
Experimental technique
(1) cerebral ischemia protection experiment
1, the reference literature method prepares imperfection cerebral ischemic model (the ligation common carotid artery merges voltage drop method): use the nembutal anesthetized rat, isolate left and right sides carotid artery and femoral artery.Connect blood pressure measuring device, ligation left and right sides common carotid artery also is depressurized to 5.3-6.00kPa (40-45mmHg) (the also not blood-letting of not ligation of Sham-operated control group tremulous pulse) from the femoral artery blood-letting, after keeping this blood pressure to make cerebral ischemia 30min, blood is refilled rat and recover the brain perfusion, this moment, the Mus brain both suffered ischemic injuries, also produced reperfusion injury.
(1) mensuration of brain water content after the cerebral ischemia: (264 ± 17g) are divided into 5 groups at random to get 55 of male rats, test preceding 6 hours oral administration gavages and be subjected to reagent thing (Sham-operated control group and the commensurability normal saline of cerebral ischemic model group filling stomach, down together), gastric infusion is once again during experiment, both be equipped with ischemia model by last legal system, duodenal administration is once again after recovering hemoperfusion, broken end is got forebrain after 3 hours, weigh, put 110 ℃ and bake, calculate brain water content % (brain water content %=(weight in wet base one dry weight)/weight in wet base * 100%) to constant weight.
(2) mensuration of cerebral ischemia hindbrain capillary permeability: get 55 (244 ± 16g of rat, male and female half and half), be divided into 5 groups at random, test preceding 6 hours oral administration gavages and be subjected to the reagent thing, gastric infusion is once again during experiment, be equipped with ischemia model by last legal system, the blue 60mg/kg of the respectively quiet notes ivens of 10min before the ligation common carotid artery, duodenal administration is once again after recovering hemoperfusion, broken end is got forebrain after 5 hours, weighs, and puts in the formamide solution, at 632nm place survey trap with spectrophotometer at 45 ℃ of following incubations after 60 hours, calculate the content (the wet brain of ug/g is heavy) of ivens orchid in the brain according to standard curve.
(3) inspection of cerebral ischemia hindbrain tectology: get 20 (259 ± 19g of rat, male and female half and half), be divided into 5 groups at random, test preceding 6 hours oral administration gavages and be subjected to the reagent thing, gastric infusion is once again during experiment, be equipped with ischemia model by last legal system, duodenal administration once breaks end after 3 hours and gets forebrain again after recovering hemoperfusion, formalin fixed, crown section, HE dyeing, the light border is checked.
2, anoxia enduring experiment under the mice normal pressure: get 56 (23.8 ± 1.8g of mice, male and female half and half), be divided into 4 groups at random, distinguish twice of gastric infusion in preceding 6 hours of experiment and 30min, mice is put (connecting an adjust blood pressure bottle makes pressure equate with extraneous) in the glass exsiccator that sodica calx is housed, airtight and timing, the record anoxia in mice death time.
3, mice broken end posttension cause for gossip is tested: get 64 of male mices (24.2 ± 1.7g), be divided into 4 groups at random, gastric infusion twice respectively when preceding 6 hours of experiment and 30min during experiment is cut mice Mus head, immediate record is dehisced the time of breathing.
(2) anticoagulation experiment
1, clotting time influence experiment: get 60 of mices (23.8 ± 1.7g, male and female half and half), be divided into 5 groups at random,, pluck eyeball during experiment and get blood and measure clotting time with capillary tube method in preceding 6 hours of experiment and 30min gastric infusion twice respectively.
2, platelet aggregation influence experiment: carry out experiment in vitro by the BronShi turbidimetry, adopt Sanguis Leporis seu oryctolagi and prepare platelet count to 5 * 10 among platelet rich plasma (PRP) and platelet poor plasma (PPP) the adjusting PRP
8Cell/L, taking liquid mixes with FRP respectively, incubation 20min, add derivant platelet activating factor (PAF) (final concentration is 7.2nmlo/L) respectively, arachidonic acid (AA) (final concentration is 0.35mmol/L), adenosine diphosphate (ADP) (ADP) (final concentration is 3umlo/L) induced platelet is assembled, and measures the maximum percentage rate of assembling of platelet with platelet aggregation instrument, and calculates the platelet aggregation inhibition rate of medicine.
Above-mentioned experimental data represents that with X ± SD all experimental result is all carried out statistical analysis with method of analysis of variance.The result:
1, notoginseng total saponin capsule to cerebral ischemia after the influence of brain water content
Cerebral ischemic model group brain water content and sham operated rats relatively have significant difference, and brain water content obviously raises, notoginseng total saponin capsule (200,100mg/kg, po) with XUESAITONG ZHUSHEYE (60kg; Brain water content obviously descends after iv) all making cerebral ischemia, alleviates cerebral edema.Simultaneously, notoginseng total saponin capsule also demonstrates tangible dose-effect relationship.
2, notoginseng total saponin capsule to cerebral ischemia after cerebrovascular permeability influence in the cerebral ischemic model group cerebral tissue blue content of ivens and the apparent in view rising of sham operated rats, this presentation of results cerebral ischemia can make cerebrovascular permeability raise, notoginseng total saponin capsule (100,200mg/kg, po) with XUESAITONG ZHUSHEYE (60mg/kg; The blue content of ivens is obviously descended, illustrate that this two medicine can suppress the rising of cerebrovascular permeability after the cerebral ischemia.
3, notoginseng total saponin capsule is to the influence of cerebral ischemia hindbrain tectology
Visible Sham-operated control group rat brain neurocyte and neurogliocyte form are normal under the border, nuclear membrane is clear, kernel is obvious, bright or light the dying of endochylema, after birth is clear, obvious pathological change appears in cerebral ischemic model group rat cerebral tissue, at forehead, top, cortex of temporal lobe and Hippocampus etc. are located visible neurocyte karyopycnosis and (dwindle triangular in shape, engrain, kernel disappears), (nuclear structure is light to be dyed in karyolysis, disappear, the nuclear profile is unclear), the neurocyte at these positions is more than half ischemic necrosis to occur and neurocyte takes off changes such as mistake, and other sees the obvious swelling of neurogliocyte, between matter vasodilation hyperemia, the loose edema of a matter is obvious.Notoginseng total saponin capsule (100,200mg/kg, po) group and XUESAITONG ZHUSHEYE (60mg/kg; Iv) organize ischemias variations such as the karyopycnosis of cerebral tissue neurocyte, karyolysis and compare obvious reduction with the cerebral ischemic model group; it is dead to have only the only a few neurocyte to occur; matter was loose between neurogliocyte swelling reached also obviously alleviates, and presents tangible ischemia protective effect.
4, notoginseng total saponin capsule is to the influence of mice normal pressure hypoxia-bearing capability
Give notoginseng total saponin capsule (200mg/kg, po) and XUESAITONG ZHUSHEYE (120mg/kg; The effect of obvious prolongation mice time-to-live is iv) all arranged.
5, notoginseng total saponin capsule is to the influence of mice broken end back mouth breathing time
Give notoginseng total saponin capsule (200mg/kg, po) and XUESAITONG ZHUSHEYE (60mg/kgiv) effect that prolongs the mice mouth breathing time is all arranged.
6, notoginseng total saponin capsule is to the influence of clotting time of mice
Give notoginseng total saponin capsule (200mg/kg, po) and XUESAITONG ZHUSHEYE (120mg/kg; The effect that prolongs clotting time is iv) all arranged.
7, notoginseng total saponin capsule is to the influence of platelet aggregation
Notoginseng total saponin capsule can significantly suppress the inductive platelet aggregation of PAF in the concentration range of 0.625-2.5mg/ml, suppression ratio reaches 15.4-88.5%, when the concentration of 2.5mg/ml, can significantly suppress the inductive platelet aggregation of ADP, suppression ratio reaches 39.5%, XUESAITONG ZHUSHEYE also has remarkable inhibitory action to PAF and the inductive platelet aggregation of ADP in the 0.625-2.5mg/ml scope, suppression ratio reaches 8.0-75.1% and 20.9-33.9%.
Claims (5)
1, a kind of notoginseng total saponin capsule, constitute by medicinal liquid and softgel shell two large divisions, it is characterized in that medicinal liquid by weight every contain Radix Notoginseng total arasaponins 40-250 milligram and contain solvent 250-400 milligram, stabilizing agent 200-500 milligram, the gelatin that contains 10 parts of weight in the softgel shell, 3.25-3.35 the glycerol of part weight, and antiseptic.
2, as the said notoginseng total saponin capsule of claim 1, it is characterized in that: solvent is one or more in liquid polyethylene glycol, isopropyl alcohol, tween 80, glycerol, propylene glycol, water and the vegetable oil.
3, as the said notoginseng total saponin capsule of claim 1, it is characterized in that: antiseptic is one or more in glycerol, propylene glycol, methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, benzyl p-hydroxybenzoate, the P-hydroxybenzoic acid phenyl ester.
4, as the preparation technology of the said notoginseng total saponin capsule of claim 1, it is characterized in that may further comprise the steps: after Radix Notoginseng total arasaponins is beaten powder and crossed the 80-120 mesh sieve, under stirring, join in the liquid polyethylene glycol gradually, heating makes the solution insulation also stir at 50-70 ℃ and makes its dissolving, add entry and glycerol etc. after the dissolving, stirring makes its mix homogeneously, filter, outgas back pelleting, drying, promptly.
5, as the preparation technology of the said notoginseng total saponin capsule of claim 1, it is characterized in that may further comprise the steps: after Radix Notoginseng total arasaponins is beaten powder and crossed the 80-120 mesh sieve, feed intake by the prescription proportioning, elder generation in partial solvent, adds the thermosol thing stabilizing agent thermosol in the residual solvent that is preheating to 35-45 ℃ more lentamente, the limit edged stirs, and then various solids are added one by one, fully mix each back that adds, moistening fully to guarantee, cross colloid mill and pulverize back pelleting, drying, promptly.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98106597A CN1111412C (en) | 1998-03-17 | 1998-03-17 | Notoginseng total saponin soft capsule and its preparation process |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98106597A CN1111412C (en) | 1998-03-17 | 1998-03-17 | Notoginseng total saponin soft capsule and its preparation process |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1228960A CN1228960A (en) | 1999-09-22 |
CN1111412C true CN1111412C (en) | 2003-06-18 |
Family
ID=5219033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN98106597A Expired - Lifetime CN1111412C (en) | 1998-03-17 | 1998-03-17 | Notoginseng total saponin soft capsule and its preparation process |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1111412C (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6500468B1 (en) * | 2002-01-03 | 2002-12-31 | Farlong Pharmaceutical, Inc. | Panax notoginsenoside composition |
CN100420444C (en) * | 2005-06-17 | 2008-09-24 | 云南白药集团股份有限公司 | Pennogenic compound liquid molecular dispersible preparation |
CN100384429C (en) * | 2006-04-07 | 2008-04-30 | 黑龙江省珍宝岛制药有限公司哈尔滨分公司 | Capsule for treating cardiac and cerebral vascular diseases and its preparing method and application |
CN105079062B (en) * | 2015-08-11 | 2018-07-20 | 昆明圣火药业(集团)有限公司 | A kind of soft capsule for removing thromboembolism and preparation method thereof and detection method |
-
1998
- 1998-03-17 CN CN98106597A patent/CN1111412C/en not_active Expired - Lifetime
Non-Patent Citations (3)
Title |
---|
《THE PRACTICAL JOURNAL OF INTEGRATING CHINESE WITH MODRN ME 1997-01-01 王淑琴,血塞通注射液治疗冠心病85例临床观察 * |
《THE PRACTICAL JOURNAL OF INTEGRATING CHINESE WITH MODRN ME 1997-01-01 王淑琴,血塞通注射液治疗冠心病85例临床观察;《时珍国药研究》VOL.7 NO.1 1995-01-01 岳峰梅,肠粘接合剂的制备及应用 * |
《时珍国药研究》VOL.7 NO.1 1995-01-01 岳峰梅,肠粘接合剂的制备及应用 * |
Also Published As
Publication number | Publication date |
---|---|
CN1228960A (en) | 1999-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080234207A1 (en) | Pharmaceutical Composition for Preventing and Treating Diabetes or Glucose Control Abnormality Comprising Ginsenosides | |
CN114246918B (en) | Traditional Chinese medicine composition for treating hashimoto thyroiditis and preparation method thereof | |
CN1565583A (en) | Chinese drugs compositions for treating diabetes and its complications | |
CN1111412C (en) | Notoginseng total saponin soft capsule and its preparation process | |
CN104042928B (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
CN103908571A (en) | Compound traditional Chinese medicine preparation for treating heart disease | |
CN106109554A (en) | A kind of compositions improving insulin resistant | |
CN112675271A (en) | Traditional Chinese medicine composition for treating internal abnormality and application thereof | |
CN1915260A (en) | Drop pills containing general saponin of notoginseng, and preparation method | |
CN1626145A (en) | Medication for treating cough | |
CN1977888B (en) | Medicinal composition of baicalin, ganoderma lucidum and salvia miltrorrhiza | |
CN1308019C (en) | Chinese medicinal composition for treating chronic pelvic inflammation and preparation method thereof | |
CN1969937B (en) | Pharmaceutical composition for treating hepatitis | |
CN104510884A (en) | Compound traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases | |
CN1730023A (en) | Hepatitis virus resistant Chinese medicinal formulation and method for preparing same | |
CN103263581A (en) | Shuangshen capsule for reducing blood sugar | |
CN113616723B (en) | Traditional Chinese medicine composition for treating chronic heart failure and preparation method thereof | |
CN110448622B (en) | Medicine for treating heat type cold and preparation method and application thereof | |
CN102240328A (en) | Traditional Chinese medicine for treating cold and preparation method thereof | |
CN1931214B (en) | Medicine composition of rhodiola root and puerarin | |
CN101966251B (en) | Medicinal composition for preventing and treating bronchial asthma and preparation and application thereof | |
Konkon et al. | Phytochemical and evaluation of hypoglycemic effect of leaves extract of Aloe buettneri A. Berger (liliaceae) in normal and alloxan-induced diabetic mice | |
RU2238755C1 (en) | Curative-prophylactic agent eliciting hepatoprotective, cholesterol- and glucose-regulating effect (variants) | |
CN100531740C (en) | Health care products for auxiliary treatment of diseases of cardio-cerebral blood vessels | |
CN1785416A (en) | Medicinal preparation for freating chololithiasis and its preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: KPC CO., LTD. Free format text: FORMER NAME: KUNMING PHARMACEUTICAL INDUSTRY GROUP CORP., LTD. |
|
CP03 | Change of name, title or address |
Address after: 650106 Kunming science and Technology Industrial Development Zone, Yunnan Province Road No. 166 Patentee after: Kun Yao Group Plc Address before: 650100, seven kilometers west of Kunming City, Yunnan Province Patentee before: Kunming Pharmaceutical Industry Group Corp., Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20030618 |
|
CX01 | Expiry of patent term |